Biomarkers are critical tools for detecting and monitoring disease, understanding pathogenic mechanisms, and tracking therapeutic responses. From proteomic profiling to AI-based algorithms, scientists ...

What are the benefits and challenges of using multiomics approaches to discover cancer biomarkers? Multiomics means that scientists are measuring more than one class of analyte, such as DNA, RNA, or ...

Diagram of the MEFE Algorithm and partial result. (a) Elastic feature extraction. (b) MEFE reduces errors by microbiome misclassification or data sparsity. (c) PCoA analysis on Real Dataset I (ASD).

Plasma proteomics offers great promise for biomarker discovery, due to the accessibility and diagnostic relevance of blood plasma. Recent advances in instrumentation, particularly the Orbitrap Astral ...

Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery market ...

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announced the launch of its biomarker discovery service, ...

Join us for a science symposium where cutting-edge biology meets transformative technology. Dive deep into molecular research using the latest multiomics advances, from the granularity of single-cell ...

Biomarker discovery opens the way for development of novel transformational technology in Autism Spectrum Disorder. FRAMINGHAM, MA / ACCESS Newswire / November 4, 2025 / Ignite Biomedical, Inc.

Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and remains the leading cause of end-stage renal disease (ESRD) worldwide.

A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson's disease in its earliest stages, before extensive brain damage has ...